HIV-associated lipodystrophy is a redistribution of body fat — loss from face and limbs, accumulation in the abdomen and trunk — associated with HIV infection and particularly with older antiretroviral drugs. Visceral fat accumulation in this setting carries metabolic and cardiovascular risk and is disfiguring. Growth hormone secretion is reduced in affected patients, which was the rationale for a releasing-hormone analogue.
The condition became less common as antiretroviral regimens changed.
Two randomised placebo-controlled trials of 26 weeks with extensions to 52, several hundred participants each, visceral fat by imaging as the primary endpoint, and improvements in triglycerides and in a patient-reported measure of abdominal distress as secondary findings. IGF-1 rose; glucose measures shifted slightly. The label carries these findings and the discontinuation finding, and requires that the drug be stopped if no response is seen.
The pages on the Falutz trials cover the data in detail.
One indication, one population, one endpoint. The approval does not extend to people without HIV, to weight loss, to body composition in healthy adults, or to any other use. The pack in this catalogue is a research material and is not the approved product.
Tesamorelin is supplied by REVIVE LAB UAE for laboratory research use only, with identity by mass spectrometry and purity by HPLC for the batch. It is not for human or veterinary use, and no dosing, administration or protocol guidance is provided.
| Format | Strength | Price | Availability |
|---|---|---|---|
| Tesamorelin Pack | 20 mg | AED 1010 | In stock |
Delivery is AED 40 flat and free on orders over AED 700. Payment is cash on delivery anywhere in the UAE, or USDT (TRC20) in advance, which takes 5% off the order total.
HIV-associated lipodystrophy is a redistribution of body fat — loss from face and limbs, accumulation in the abdomen and trunk — associated with HIV infection and particularly with older antiretroviral drugs. Visceral fat accumulation in this setting carries metabolic and cardiovascular risk and is disfiguring. Growth hormone secretion is reduced in affected patients, which was the rationale for a releasing-hormone analogue.
No. REVIVE LAB UAE supplies research materials and provides no dosing, administration or protocol guidance of any kind. Every product is sold for laboratory research use only and is not for human or veterinary consumption.
Stock is held in Dubai. An order confirmed before 4 PM Dubai time is dispatched the same working day, reaching Dubai and Abu Dhabi the same day and the remaining emirates within 24 hours. Delivery is AED 40 flat and free over AED 700.
Supplied for laboratory research use only. Not for human or veterinary consumption. REVIVE LAB UAE provides no dosing, administration or protocol guidance.